Literature DB >> 3377942

Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery.

F O Holley1, C van Steennis.   

Abstract

We have investigated the use of constant-rate delivery of fentanyl by i.v. and transdermal routes for the treatment of pain after major surgery. Forty-five males, ASA I-III, received in a double-blinded fashion either placebo (n = 6) or fentanyl (n = 39) i.v. at one of four dose rates (25, 50, 100 or 125 micrograms h-1). Stable serum concentrations of fentanyl were produced by the end of surgery and were maintained for a total of 24 h. Calculated clearance of fentanyl was 1.05 +/- 0.38 litre min-1 and was not related to weight or age. Both the 100- and 125-micrograms h-1 dose rates produced significant analgesic efficacy as assessed by postoperative morphine requirements. Mean serum concentrations of fentanyl in these groups were 1.42 +/- 0.14 (SD) and 1.90 +/- 0.30 ng ml-1, respectively. One of 10 patients receiving fentanyl 100 micrograms h-1 and three of nine patients receiving 125 micrograms h-1 had evidence of respiratory depression. Eight additional patients were treated with a transdermal drug delivery system containing fentanyl (TTS-fentanyl). Steady-state serum concentrations in this group were 2.15 +/- 0.92 (SD) ng ml-1. Post-operative morphine requirements were minimal (less than 0.5 mg h-1) and PaCO2 remained acceptable in all patients. Serum concentrations of fentanyl increased slowly (15 h to plateau) and decreased slowly (apparent half-life, 21 h). We conclude that delivery of analgesic doses of fentanyl is feasible by the transdermal route.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3377942     DOI: 10.1093/bja/60.6.608

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  33 in total

Review 1.  Management of post-operative pain.

Authors:  G Smith
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

2.  Fentanyl transdermal system. Pain management at home.

Authors:  M A Woodroffe; H Hays
Journal:  Can Fam Physician       Date:  1997-02       Impact factor: 3.275

3.  Transdermal-mucosal sedative and analgesic delivery.

Authors:  J B Streisand
Journal:  West J Med       Date:  1990-09

Review 4.  Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.

Authors:  W Jeal; P Benfield
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 5.  Transdermal patches: history, development and pharmacology.

Authors:  Michael N Pastore; Yogeshvar N Kalia; Michael Horstmann; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2015-03-18       Impact factor: 8.739

6.  Monoclonal Antibodies for Combating Synthetic Opioid Intoxication.

Authors:  Lauren C Smith; Paul T Bremer; Candy S Hwang; Bin Zhou; Beverly Ellis; Mark S Hixon; Kim D Janda
Journal:  J Am Chem Soc       Date:  2019-06-25       Impact factor: 15.419

7.  Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market.

Authors:  Privia A Randhawa; Rupinder Brar; Seonaid Nolan
Journal:  CMAJ       Date:  2020-01-20       Impact factor: 8.262

8.  Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta).

Authors:  Gregory W Salyards; Marie-Josee Lemoy; Heather K Knych; Ashley E Hill; Kari L Christe
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-07-01       Impact factor: 1.232

9.  Transdermal fentanyl for the treatment of pain after major urological operations. A randomized double-blind comparison with placebo using intravenous patient-controlled analgesia.

Authors:  K A Lehmann; C Einnolf; H J Eberlein; R Nagel
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.

Authors:  Carla Ripamonti; Elena Fagnoni; Tiziana Campa; Cinzia Brunelli; Franco De Conno
Journal:  Support Care Cancer       Date:  2006-02-17       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.